Navidea Biopharmaceuticals Inc  

(Public, NYSEMKT:NAVB)   Watch this stock  
Find more results for OTC:NEOP
+0.04 (2.99%)
Apr 29 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.31 - 1.38
52 week 0.75 - 2.49
Open 1.33
Vol / Avg. 683,472.00/499,335.00
Mkt cap 214.68M
P/E     -
Div/yield     -
EPS -0.19
Shares 155.57M
Beta 0.52
Inst. own 34%
May 10, 2016
Q1 2016 Navidea Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 23, 2016
Q4 2015 Navidea Biopharmaceuticals Inc Earnings Release
Mar 23, 2016
Q4 2015 Navidea Biopharmaceuticals Inc Earnings Call - Webcast
Feb 8, 2016
Navidea Biopharmaceuticals Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -76.13% -213.76%
Operating margin -60.57% -158.43%
EBITD margin - -135.70%
Return on average assets -80.82% -211.40%
Return on average equity - -
Employees 56 -
CDP Score - -


5600 Blazer Pkwy Ste 200
DUBLIN, OH 43017-7550
United States - Map
+1-614-7937500 (Phone)
+1-614-7937522 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Navidea Biopharmaceuticals, Inc. is a precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. The Company is developing multiple precision-targeted products based on the Manocept platform. The Manocept platform serves as the molecular backbone of Lymphoseek (technetium Tc 99m tilmanocept) injection, the first product developed by the Company based on the platform. Lymphoseek is a receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. NAV4694 is a fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment. NAV5001 is an iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders.

Officers and directors

Michael M. Goldberg M.D. Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Ricardo J. Gonzalez Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Brent L. Larson CPA Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 52
Bio & Compensation  - Reuters
Jed A. Latkin Interim Chief Operating Officer
Age: 41
Bio & Compensation  - Reuters
Frederick O. Cope Ph.D. Senior Vice President - Pharmaceutical Research and Clinical Development, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
William J. Regan Senior Vice President - Global Regulatory Affairs and Quality Chief Compliance Officer
Age: 63
Bio & Compensation  - Reuters
Thomas J. Klima Senior Vice President and Chief Commercial Officer
Age: 43
Bio & Compensation  - Reuters
Anthony S. Fiorino M.D. Ph.D. Director
Age: 48
Bio & Compensation  - Reuters
Mark I. Greene M.D. Ph.D. Director
Age: 67
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Director
Age: 59
Bio & Compensation  - Reuters